CARGO THERAPEUTICS INC (CRGX) Fundamental Analysis & Valuation

NASDAQ:CRGX • US14179K1016

Current stock price

4.47 USD
-0.07 (-1.54%)
At close:
4.47 USD
0 (0%)
After Hours:

This CRGX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. CRGX Profitability Analysis

1.1 Basic Checks

  • CRGX had negative earnings in the past year.
  • CRGX had a negative operating cash flow in the past year.
CRGX Yearly Net Income VS EBIT VS OCF VS FCFCRGX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -85.76%, CRGX is doing worse than 71.14% of the companies in the same industry.
  • CRGX has a Return On Equity (-93.30%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -85.76%
ROE -93.3%
ROIC N/A
ROA(3y)-154.01%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CRGX Yearly ROA, ROE, ROICCRGX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 1K 2K 3K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for CRGX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRGX Yearly Profit, Operating, Gross MarginsCRGX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. CRGX Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for CRGX has been increased compared to 1 year ago.
  • There is no outstanding debt for CRGX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CRGX Yearly Shares OutstandingCRGX Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 10M 20M 30M 40M
CRGX Yearly Total Debt VS Total AssetsCRGX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

  • An Altman-Z score of 2.91 indicates that CRGX is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • The Altman-Z score of CRGX (2.91) is better than 71.69% of its industry peers.
  • CRGX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.91
ROIC/WACCN/A
WACCN/A
CRGX Yearly LT Debt VS Equity VS FCFCRGX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 100M -100M 200M 300M 400M

2.3 Liquidity

  • CRGX has a Current Ratio of 12.37. This indicates that CRGX is financially healthy and has no problem in meeting its short term obligations.
  • CRGX's Current ratio of 12.37 is amongst the best of the industry. CRGX outperforms 85.48% of its industry peers.
  • A Quick Ratio of 12.37 indicates that CRGX has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 12.37, CRGX belongs to the top of the industry, outperforming 85.48% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 12.37
Quick Ratio 12.37
CRGX Yearly Current Assets VS Current LiabilitesCRGX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. CRGX Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 92.79% over the past year.
EPS 1Y (TTM)92.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1.96%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 5.88% on average over the next years.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y21.22%
EPS Next 2Y13.77%
EPS Next 3Y12.68%
EPS Next 5Y5.88%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CRGX Yearly Revenue VS EstimatesCRGX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 200M 400M 600M
CRGX Yearly EPS VS EstimatesCRGX Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -5 -10 -15 -20

More info and screens

Find the best growth stocksShow best growing peers

0

4. CRGX Valuation Analysis

4.1 Price/Earnings Ratio

  • CRGX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CRGX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRGX Price Earnings VS Forward Price EarningsCRGX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRGX Per share dataCRGX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

  • A more expensive valuation may be justified as CRGX's earnings are expected to grow with 12.68% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.77%
EPS Next 3Y12.68%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CRGX Dividend Analysis

5.1 Amount

  • No dividends for CRGX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

CRGX Fundamentals: All Metrics, Ratios and Statistics

CARGO THERAPEUTICS INC

NASDAQ:CRGX (8/18/2025, 9:25:47 PM)

After market: 4.47 0 (0%)

4.47

-0.07 (-1.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06
Earnings (Next)11-10
Inst Owners98.83%
Inst Owner Change-99.74%
Ins Owners0.35%
Ins Owner Change0%
Market Cap216.17M
Revenue(TTM)N/A
Net Income(TTM)-221.78M
Analysts49.09
Price Target5.61 (25.5%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-35.97%
Min EPS beat(2)-65.12%
Max EPS beat(2)-6.83%
EPS beat(4)2
Avg EPS beat(4)-11.28%
Min EPS beat(4)-65.12%
Max EPS beat(4)23.75%
EPS beat(8)4
Avg EPS beat(8)-199.15%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.13%
PT rev (3m)-48.48%
EPS NQ rev (1m)-8.33%
EPS NQ rev (3m)-16.77%
EPS NY rev (1m)-2.34%
EPS NY rev (3m)-6.12%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.91
P/tB 0.91
EV/EBITDA N/A
EPS(TTM)-3.66
EYN/A
EPS(NY)-2.62
Fwd EYN/A
FCF(TTM)-3.97
FCFYN/A
OCF(TTM)-3.92
OCFYN/A
SpS0
BVpS4.92
TBVpS4.92
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -85.76%
ROE -93.3%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-154.01%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 28.26%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.37
Quick Ratio 12.37
Altman-Z 2.91
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)322.35%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)92.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1.96%
EPS Next Y21.22%
EPS Next 2Y13.77%
EPS Next 3Y12.68%
EPS Next 5Y5.88%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-0.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year25.28%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-266.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-288.58%
OCF growth 3YN/A
OCF growth 5YN/A

CARGO THERAPEUTICS INC / CRGX Fundamental Analysis FAQ

What is the ChartMill fundamental rating of CARGO THERAPEUTICS INC (CRGX) stock?

ChartMill assigns a fundamental rating of 3 / 10 to CRGX.


What is the valuation status for CRGX stock?

ChartMill assigns a valuation rating of 0 / 10 to CARGO THERAPEUTICS INC (CRGX). This can be considered as Overvalued.


What is the profitability of CRGX stock?

CARGO THERAPEUTICS INC (CRGX) has a profitability rating of 0 / 10.


Can you provide the financial health for CRGX stock?

The financial health rating of CARGO THERAPEUTICS INC (CRGX) is 8 / 10.